Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Items (Tables)

v3.20.2
Composition of Certain Financial Statement Items (Tables)
9 Months Ended
Jun. 28, 2020
Balance Sheet Related Disclosures [Abstract]  
Accounts Receivable
Accounts Receivable, net (in millions)
June 28,
2020
September 29,
2019
Trade, net of allowances for doubtful accounts $ 928    $ 1,046   
Unbilled 907    1,411   
Other 12    14   
$ 1,847    $ 2,471   
Inventories
Inventories (in millions)
June 28,
2020
September 29,
2019
Raw materials $ 110    $ 77   
Work-in-process 942    667   
Finished goods 1,291    656   
$ 2,343    $ 1,400   
Equity Method and Non-marketable Equity Investments The carrying values of our equity method and non-marketable equity investments are recorded in other noncurrent assets and were as follows (in millions):
June 28,
2020
September 29,
2019
Equity method investments $ 213    $ 343   
Non-marketable equity investments 750    787   
$ 963    $ 1,130   
Investment and Other Income, Net
Investment and Other Income, Net (in millions)
Three Months Ended Nine Months Ended
June 28,
2020
June 30,
2019
June 28,
2020
June 30,
2019
Interest and dividend income $ 30    $ 80    $ 135    $ 224   
Net gains on marketable securities 117    315    183    296   
Net gains on other investments 48      84    47   
Net gains on deferred compensation plan assets 57    12    16    10   
Impairment losses on other investments (12)   (42)   (349)   (111)  
Net gains (losses) on derivative investments   —      (10)  
Equity in net losses of investees (6)   (22)   (21)   (79)  
Net losses on foreign currency transactions (6)   (5)   (4)   —   
$ 229    $ 344    $ 46    $ 377